OHB-401
Diabetic Macular Edema
Pre-clinicalActive
Key Facts
About Oak Hill Bio
Oak Hill Bio is a UK-based biotech with a unique 'relay' business model, acquiring and advancing late-stage rare disease programs abandoned by larger pharmaceutical companies. Its lead assets are rugonersen (OHB-724), an ASO for Angelman syndrome entering Phase 3, and OHB-607, a recombinant protein for bronchopulmonary dysplasia prevention in preemies, currently in Phase 2b with partner Chiesi. The company operates with a lean, asset-centric approach, aiming to de-risk development and deliver first- or best-in-class therapies to underserved patient populations.
View full company profileTherapeutic Areas
Other Diabetic Macular Edema Drugs
| Drug | Company | Phase |
|---|---|---|
| Not Specified (Ophthalmology Program) | Therini Bio | Clinical-stage |
| EY-001 | EyeYon Medical | Phase 1 |
| TAK-648 | Thermo Fisher Scientific | Phase 2 |
| AXPAXLI (OTX-TKI) | Ocular Therapeutix | Phase 3 |
| BGE-102 | BioAge Labs | Phase 1b/2a |
| 4D-150 | 4D Molecular Therapeutics | Phase 3 |